Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (CINGAL®) to Provide Symptomatic Relief of Osteoarthritis of Hip Joint

NCT04640298 is registered in ClinicalTrials.gov with Anika Therapeutics, Inc. as lead sponsor.

NCT NCT04640298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04640298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (CINGAL®) to Provide Symptomatic Relief of Osteoarthritis of Hip Joint
Lead sponsor
Anika Therapeutics, Inc.
Phase
Not applicable
Overall status
Completed
Start date
January 16, 2021
Completion date
September 10, 2021
Enrollment
25 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, hip